New Approaches to the Treatment of Osteoporosis
- 18 February 2011
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 62 (1), 307-322
- https://doi.org/10.1146/annurev-med-061709-145401
Abstract
Although safe and effective agents are currently available to treat osteoporosis, fragility fractures remain a significant problem worldwide. Recent improvements in the understanding of the cellular, biochemical, and molecular pathways of bone biology have led to the development of newer agents to treat osteoporosis, which may lead to further improvements in outcomes. In this review, we summarize the most recent advances in the field, including new modes of administration of existing drug classes, various approaches to combination therapy, and drugs with novel mechanisms of action to treat osteoporosis.Keywords
This publication has 89 references indexed in Scilit:
- Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosisNature Medicine, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisThe New England Journal of Medicine, 2009
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate CancerThe New England Journal of Medicine, 2009
- Designing the ideal selective estrogen receptor modulator-an achievable goal?Menopause, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerThe New England Journal of Medicine, 2009
- Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the DuodenumCell, 2008
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trialBone, 2008
- An estimate of the worldwide prevalence and disability associated with osteoporotic fracturesOsteoporosis International, 2006
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJama-Journal Of The American Medical Association, 2006
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJama-Journal Of The American Medical Association, 2004